Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Deloitte
Express Scripts
Federal Trade Commission
Julphar
Medtronic
Covington
Argus Health

Generated: December 9, 2018

DrugPatentWatch Database Preview

Litigation Details for MYLAN LABORATORIES, INC. v. LEAVITT (D.C. 2007)

« Back to Dashboard

Small Molecule Drugs cited in MYLAN LABORATORIES, INC. v. LEAVITT
The small molecule drugs covered by the patents cited in this case are ➤ Try a Free Trial , ➤ Try a Free Trial , and ➤ Try a Free Trial .
Biologic Drugs cited in MYLAN LABORATORIES, INC. v. LEAVITT
The biologic drug covered by the patents cited in this case is ➤ Try a Free Trial .

Details for MYLAN LABORATORIES, INC. v. LEAVITT (D.C. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-03-26 1 Complaint 4,572,909 (“the ‘909 patent”) and U.S. Patent No. 4,879,303 (“the ‘303 patent”) The ‘909 patent expired on July…violate the ‘909 patent and the ‘303 patent because l Drug Price Competition and Patent Term Restoration…held two patents that it contended covered different aspects of amlodipine besylate, U.S. Patent No. 4,572,909…manufacturers to challenge invalid patents, such as Pfizer’s ‘303 patent. See id. If the FDA permits other…July 31, 2002; the ‘303 patent expired on March 25, 2007. 9. Since 1992, Pfizer has commercially marketed External link to document
2007-03-30 15 Motion to Intervene Wells identified a for- tion issued as U.S. Patent No. 4,572,909 (“the 909 mulation for amlodipine…303 patent, and Philip D. Segrest, Jr. that if the 303 patent were…any product comprising amlodipine Patent No. 4,879,303 (“the 303 patent”) to Pfizer, in- besylate covered…claims 1-3 of the 303 patent. The ANDA by) the claims of the 303 patent until September 25,… FN2 patent”) on February 25, 1986. The 909 patent “excellent capsules External link to document
2007-04-02 19 Motion to Intervene certification to Pfizer’s U.S. Patent No. 4,879,303 (“the c303 patent”), certifying that Mutual was not… 35 5(j)(2)(A)(vii)(lV) to Ptizer’s amlodipine patents, Mylan asserts that it is entitled to a 180-day…approval of its ANDA until the expiration of the ‘303 patent on l\/larch 25, 2007. By virtue of Mutual’s Paragraph…until six months alter the expiration of the ‘303 patent (September 25, 2007). ARGUMENT l\/lutual, like…being the first ANDA filer to challenge Pfizer’s patents. As such, Mylan is entitled to reap the benefits External link to document
2007-03-26 3 Motion for Preliminary Injunction United States Patent Nos. 4,572,909 (the ‘909 patent) and Patent No. 4,879,303 (the ‘303 patent).1 The parties…‘909 patent on amlodipine and two prior art patents - the Schmidt patent and the Spiegel patent. …, at 24.) The U.S. patent agents would rely on the U.K patent lawyers or U.K patent agents to provide…provided in the ‘909 patent. (See ‘909 Patent, MTX 1.) 151. The ‘909 patent recites twelve…drug claimed in a patent or the use of which is claimed in a patent is an act of patent infringement if External link to document
2007-04-11 30 Amended Complaint that Pfizer’s patent 4,879,303 (“the ‘303 patent”) is invalid? Can FDA treat the ‘303 patent as invalid …the ‘909 patent”) and U.S. Patent No. 4,8'}'9,303 (“the ‘303 patent”) The ‘909 patent expired …held two patents that it contended covered different aspects of amlodipine bcsyiate, U.S. Patent No. 4,5…besylate tablets would not violate the ‘909 patent and the ‘303 patent because they were invalid, unenforceable…not violate the ’303 patent 17. On Juiy 30, 2003, Pfizer sued Apotex for patent infringement in the United External link to document
2007-04-13 31 Motion for Bond was protected by a patent owned by Pfizer—Patent No. 4,879,303 (“the ’303 Patent”). The companies who… As a result of these ANDAs, Pfizer brought patent infringement suits against Mylan and Apotex (among…Appeals entered a judgment finding Pfizer’s ’303 patent invalid. Pfizer Inc. v. Apotex, Inc., No. 06-1261…Two days later, on March 25, 2007, Pfizer’s ’303 patent expired. Apotex, not Mylan, is the only…litigant sued by Pfizer to successfully show the ’303 patent to be invalid. Nevertheless, Mylan is the only External link to document
2007-04-13 32 Motion for Leave to File 2007 expiration of Pfizer’s patent, U.S. Patent No. 4,879,303 (“the ‘303 patent”). In its letter, the FDA…the BPCA, the expiration of U.S. Patent No. 4,879,303 (“the ‘303 patent”) marked the beginning of a six-month…of the patent (including any patent extensions); or (ii) a listed patent for which…underlying patent expired, it would have provided that exclusivity would be forfeited upon patent expiration… six months after the date the patent expires (including any patent extensions)[.] 21 U.S.C. § 355a External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Accenture
US Department of Justice
US Army
Daiichi Sankyo
Fuji
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.